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background 
 
Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no ef-
fective treatment. We tested the ability of palifermin (recombinant human keratinocyte
growth factor) to decrease oral mucosal injury induced by cytotoxic therapy.
 
methods 
 
This double-blind study compared the effect of palifermin with that of a placebo on the
development of oral mucositis in 212 patients with hematologic cancers; 106 patients
received palifermin (60 µg per kilogram of body weight per day) and 106 received a pla-
cebo intravenously for three consecutive days immediately before the initiation of con-
ditioning therapy (fractionated total-body irradiation plus high-dose chemotherapy) and
after autologous hematopoietic stem-cell transplantation. Oral mucositis was evaluated
daily for 28 days after transplantation.
 
results 
 
The incidence of oral mucositis of World Health Organization (WHO) grade 3 or 4 was
63 percent in the palifermin group and 98 percent in the placebo group (P<0.001).
Among patients with this degree of mucositis, the median duration of mucositis was
6 days (range, 1 to 22) in the palifermin group and 9 days (range, 1 to 27) in the placebo
group. Among all patients, regardless of the occurrence of mucositis, the median dura-
tion of oral mucositis of WHO grade 3 or 4 was 3 days (range, 0 to 22) in the palifermin
group and 9 days (range, 0 to 27) in the placebo group (P<0.001). As compared with
placebo, palifermin was associated with significant reductions in the incidence of
grade 4 oral mucositis (20 percent vs. 62 percent, P<0.001), patient-reported soreness
of the mouth and throat (area-under-the-curve score, 29.0 [range, 0 to 98] vs. 46.8
[range, 0 to 110]; P<0.001), the use of opioid analgesics (median, 212 mg of morphine
equivalents [range, 0 to 9418] vs. 535 mg of morphine equivalents [range, 0 to 9418],
P<0.001), and the incidence of use of total parenteral nutrition (31 percent vs. 55 per-
cent, P<0.001). Adverse events, mainly rash, pruritus, erythema, mouth and tongue dis-
orders, and taste alteration, were mild to moderate in severity and were transient.
 
conclusions 
 
Palifermin reduced the duration and severity of oral mucositis after intensive chemother-
apy and radiotherapy for hematologic cancers.
abstract
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igh-dose chemotherapy and ra-
 
diotherapy followed by hematopoietic
stem-cell support is a well-established
treatment for hematologic cancers. Oral mucositis
develops and requires treatment in approximately
70 to 80 percent of patients receiving radiation-
based conditioning treatments.
 
1,2
 
 The incidence
and severity of oral mucositis vary with the condi-
tioning regimen.
Oral mucositis results from injury to epithelial
cells that line the oral cavity. The damage causes
changes ranging from mild atrophy to severe ulcer-
ation. Serious consequences include pain requiring
opioid analgesia, potentially life-threatening infec-
tions, inadequate nutrition requiring parenteral
feeding, and prolonged hospitalization.
 
1-5
 
 Current-
ly, no standard therapy prevents or treats severe oral
mucositis.
 
6,7
 
Keratinocyte growth factor is a 28-kD, heparin-
binding member of the family of fibroblast growth
factors that was originally isolated from pulmonary
fibroblasts as a protein (FGF-7) with keratinocyte-
stimulating activity. Palifermin (recombinant hu-
man keratinocyte growth factor) is an N-terminal,
truncated version of endogenous keratinocyte
growth factor with biologic activity similar to that
of the native protein, but with increased stability.
 
8
 
In animal models of chemotherapy, radiotherapy,
and hematopoietic stem-cell transplantation,
 
9,10
 
palifermin protected several types of epithelial tis-
sues. A phase 1 trial indicated that palifermin at
doses of up to 80 µg per kilogram of body weight
per day for three consecutive days was not associat-
ed with major adverse events.
 
11
 
 We evaluated the
efficacy and safety of palifermin in reducing the du-
ration and severity of oral mucositis and its sequelae
(soreness of the mouth and throat, use of opioid an-
algesics and total parenteral nutrition, and infec-
tions) in patients with hematologic cancers who
were undergoing autologous hematopoietic stem-
cell transplantation after receiving total-body irradi-
ation and high-dose chemotherapy.
 
patients
 
The institutional review board at each of the 13 study
sites approved the study protocol; all patients gave
written informed consent before all study-related
procedures. This study enrolled patients who were
at least 18 years of age, had a Karnofsky perfor-
mance-status score of at least 70, and were sched-
uled to undergo autologous stem-cell transplanta-
tion after receiving a conditioning regimen
 
12-15
 
 of
fractionated total-body irradiation plus etoposide
and cyclophosphamide for non-Hodgkin’s lympho-
ma, Hodgkin’s disease, acute myelogenous leuke-
mia, acute lymphoblastic leukemia, chronic lym-
phocytic leukemia, or multiple myeloma. Patients
were to have at least 1.5¬10
 
6
 
 cryopreserved CD34+
cells per kilogram available for transplantation and
adequate cardiac, pulmonary, renal, and hepatic
function, as determined by institutional guidelines.
 
study drug
 
Palifermin and its matching placebo were manu-
factured and packaged by Amgen. The placebo con-
tained all the ingredients of the palifermin prepa-
ration (i.e., 10 mM histidine [pH 6.5], 2 percent
sucrose, 4 percent mannitol, and 0.01 percent
polysorbate 20) except palifermin.
 
study design
 
In this placebo-controlled, double-blind, phase 3
trial, patients were randomly assigned in a 1:1 ratio
(stratified according to center and type of hemato-
logic cancer) to receive palifermin (60 µg per kilo-
gram per day) or placebo intravenously for three
consecutive days, starting three days before the ini-
tiation of total-body irradiation. After the condition-
ing regimen was administered, patients received
three additional doses
 
16
 
 of palifermin or placebo on
days 0, 1, and 2 after transplantation. Filgrastim
(Neupogen, Amgen) (5 µg per kilogram per day)
was administered to all patients daily from the day
of transplantation until the neutrophil count re-
covered.
Conditioning therapy and supportive care were
administered according to standard institutional
practice. Total-body irradiation (total, 1200 cGy)
was delivered in 6, 8, or 10 fractions over a period
of three or four days, with at least six hours be-
tween fractions, before chemotherapy was admin-
istered. Chemotherapy included intravenous eto-
poside (60 mg per kilogram) the day after the last
radiation fraction (four days before transplantation)
and one dose of cyclophosphamide (100 mg per ki-
logram) two days before transplantation. Patients
received peripheral-blood hematopoietic stem cells
collected after mobilization by means of either cyto-
kines or chemotherapy with or (for one patient)
without cytokines.
Oral mucositis was assessed with the use of three
scales: the five-grade World Health Organization
h
methods
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(WHO) oral-toxicity scale
 
17
 
 (primary scale), the five-
grade Radiation Therapy Oncology Group (RTOG)
acute radiation–morbidity scoring criteria for mu-
cous membranes,
 
18
 
 and the four-grade Western
Consortium for Cancer Nursing Research (WCCNR)
revised staging system for oral mucositis.
 
19
 
 At each
center, Clinical Assistance Programs trained evalu-
ation-team members to assess and document oral
mucositis. Each patient was assessed daily for oral
mucositis beginning 8 days before transplantation
and continuing for 28 days after transplantation or
until severe oral mucositis had resolved (i.e., re-
turned to WHO grade 0, 1, or 2).
Data on patient-reported outcomes (soreness of
the mouth and throat and ability to participate in
the activities of daily living) were collected with the
use of a daily questionnaire. The functional and
physical well-being domains of the Functional As-
sessment of Cancer Therapy general question-
naire
 
20
 
 were collected daily from 12 days before
transplantation to 28 days after transplantation
(total, 41 days).
Information concerning the use of parenteral or
transdermal narcotic analgesics was collected daily.
Total parenteral nutrition was given according to
the standards of each study site.
Antibodies against palifermin were assayed by
an electrochemiluminescence-based immunoassay
(IGEN International). Any positive test was fol-
lowed by retesting for neutralizing antibodies with
a cell-based assay. Laboratory assessments included
routine hematologic and blood chemical tests and
measurement of serum amylase and lipase concen-
trations.
The study was designed by Amgen and the prin-
cipal investigators, who also recruited the patients
and collected the data. The investigators and Ms.
Chen and Dr. Elhardt of Amgen analyzed the data;
all investigators had access to the data. The decision
to publish was made by the investigators and Am-
gen; no limitations were imposed by the sponsor.
The lead investigator wrote the article with editori-
al assistance from Amgen.
 
efficacy and safety end points
 
Analyses of all efficacy and safety end points in-
cluded all patients who underwent randomization
and received at least one dose of study medication.
The prespecified primary end point was the dura-
tion of oral mucositis of WHO grade 3 (inability to
swallow solid food) or 4 (no form of oral alimenta-
tion possible); the duration was considered to be
zero days among patients who did not have oral
mucositis.
Other end points included the incidence of oral
mucositis of WHO grade 3 or 4, the duration of oral
mucositis of WHO grade 3 or 4 among patients with
this adverse effect, the incidence of WHO grade 4
oral mucositis, the duration of WHO grade 4 oral
mucositis among patients with this adverse effect,
the duration of oral mucositis of WHO grade 2
(moderate) or higher, the duration of oral mucosi-
tis of RTOG grade 3 or 4, the duration of lesions
of WCCNR grade 2 or 3, the area under the curve
(AUC) for patient-reported outcomes of soreness of
the mouth and throat and swallowing limitations
plotted against time, scores for the Functional As-
sessment of Cancer Therapy general questionnaire,
and the total dose and duration of parenteral or
transdermal opioid analgesics. Additional explor-
atory end points included the incidence of febrile
neutropenia, the incidence of infections, and the in-
cidence of the use of total parenteral nutrition.
Safety was assessed on the basis of the inci-
dence of adverse events, graded on a five-point scale
 
* This category includes acute lymphoblastic leukemia (one patient in the palifer-
min group), acute myelogenous leukemia (one patient in the palifermin group 
and four in the placebo group), and chronic lymphocytic leukemia (one patient 
 
in the placebo group) in complete remission.
 
Table 1. Baseline Characteristics of the Patients.
Characteristic
Palifermin 
Group
(N=106)
Placebo
Group
(N=106)
 
Male sex — no. (%) 59 (56) 72 (68)
Age — yr
Median 48 49
Range 18–69 19–68
Diagnosis — no. (%)
Non-Hodgkin’s lymphoma 72 (68) 69 (65)
Hodgkin’s disease 21 (20) 23 (22)
Multiple myeloma 11 (10) 9 (8)
Leukemia* 2 (2) 5 (5)
Karnofsky performance-status score — no. (%)
70 3 (3) 1 (1)
80 15 (14) 19 (18)
90 59 (56) 58 (55)
100 29 (27) 28 (26)
Total no. of CD34+ cells reinfused — ¬10
 
¡6
 
/kg
Median 5.2 5.0
Range 1.8–87.0 1.5–41.0
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(a score of 1 indicates mild adverse effects, and a
score of 5 fatal adverse effects); changes in clinical
laboratory values; the occurrence of antibodies
against palifermin; and the rates of progression-free
survival and secondary cancers during follow-up.
 
statistical analysis
 
The planned sample size of 210 patients (105 per
group) was chosen to provide the study with the sta-
tistical power to detect a minimal mean (±SD) dif-
ference between groups in the duration of severe
oral mucositis of more than 3.0 ± 6.6 days, with the
use of a t-test with 90 percent power and a two-sided
significance level of 5 percent. For the end points in-
volving the duration of oral mucositis, missing data
with two adjacent observed assessments were as-
signed the poorer of the two adjacent values. For
each patient whose oral mucositis had not resolved
by the end of the study we imputed the duration by
assigning the mean duration among all patients
who had severe oral mucositis for as long as or long-
er than the patient had it before the study ended.
Treatment groups were compared by means of the
generalized Cochran–Mantel–Haenszel method
stratified according to study center.
 
21
 
 The test sta-
tistic was based on the within-stratum standardized
midranks. Secondary end points were evaluated in
a prespecified order only after the primary end point
was determined to be statistically significant. All
statistical tests were two-sided at the 0.05 level of
significance. The Kaplan–Meier method
 
22
 
 was used
to estimate the rate of progression-free survival.
 
patients
 
Between March 23, 2001, and October 23, 2002, 245
patients were screened, 214 (107 per group) were
randomly assigned to a treatment group, and 212
(106 per group) received at least one dose of pali-
fermin or placebo and were included in the safety
and efficacy analyses. The center that enrolled the
most patients enrolled 19 percent of them.
The baseline characteristics of the patients were
similar in the two groups (Table 1). Of the 212 pa-
tients, 88 (83 percent) in the palifermin group and
86 (81 percent) in the placebo group had a baseline
Karnofsky performance-status score of at least 90.
All patients had received prior chemotherapy; 88
percent of those in the palifermin group and 92 per-
cent of those in the placebo group had received no
prior radiotherapy. Radiotherapy schedules were
similar in the two groups. A combination of chemo-
therapy and cytokines was used for CD34+ cell mo-
bilization in 75 percent of patients in the palifermin
group and 72 percent of patients in the placebo
group. Most patients (92 percent of those in the pali-
fermin group and 93 percent of those in the placebo
group) received acyclovir or a similar antiviral drug.
Similar numbers of patients in both groups com-
pleted the study: 103 patients in the palifermin
results
 
* P values were calculated with the use of the generalized Cochran–Mantel–
Haenszel test stratified according to study center.
† P<0.001 for the two-part statistical model, which simultaneously considered 
the incidence of oral mucositis of WHO grade 3 or 4 and the duration of oral 
mucositis of WHO grade 3 or 4 among patients with this adverse effect.
‡ AUC denotes area under the curve of outcome plotted against time. A Likert 
scale was used. For Functional Assessment of Cancer Therapy general score, 
higher scores indicate a more favorable response (range of possible scores, 
0 to 4), whereas higher scores for soreness of the mouth and throat and swal-
 
lowing limitations indicate a worse response (range of possible scores, 0 to 4).
 
Table 2. Effect of Palifermin on Oral Mucositis of WHO Grade 3 or 4 
and Patient-Reported Outcomes.
Variable
Palifermin
Group
(N=106)
Placebo
Group
(N=106) P Value*
Oral mucositis of WHO grade 3 or 4
 
Incidence — no. of patients (%)† 67 (63) 104 (98) <0.001
Duration — days
All patients <0.001
Median 3.0 9.0
Range 0–22 0–27
Patients with oral mucositis of 
WHO grade 3 or 4
<0.001
Median 6.0 9.0
Range 1–22 1–27
 
Patient-reported outcomes (AUC)‡
 
Score for soreness of mouth and throat <0.001
Median 29.0 46.8
Range 0–98 0–110
Swallowing-limitation score <0.001
Median 22.5 38.3
Range 0–104 0–104
Functional Assessment of Cancer 
Therapy general score
Physical well-being domain
Median 736.6 712.1 0.003
Range 176–1033 176–1014
Functional well-being domain
Median 546.1 542.5 0.036
Range 93–985 93–1043
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group (97 percent) and 102 patients in the placebo
group (96 percent).
 
efficacy
 
Oral mucositis of WHO grade 3 or 4 developed in
67 of 106 patients in the palifermin group (63 per-
cent) and 104 of 106 patients in the placebo group
(98 percent, P<0.001) (Table 2). The median dura-
tion of oral mucositis of grade 3 or 4 among pa-
tients with this adverse effect was 6.0 days (range,
1 to 22) in the palifermin group and 9.0 days (range,
1 to 27) in the placebo group (P<0.001) (Table 2).
The median duration of oral mucositis of WHO
grade 3 or 4 among all patients was 3.0 days (range,
0 to 22) in the palifermin group and 9.0 days (range,
0 to 27) in the placebo group (P<0.001) (Table 2).
This result — the primary end point — was repro-
ducible when the analysis was performed according
to center, type of hematologic cancer, or number of
fractions of irradiation (Fig. 1). A two-part statisti-
cal model,
 
23
 
 which simultaneously considered the
incidence of oral mucositis of WHO grade 3 or 4 and
the duration of oral mucositis of WHO grade 3 or
4 among patients with this adverse effect, showed
significant improvements in the palifermin group,
as compared with the placebo group (P<0.001) (Ta-
ble 2).
The incidence of oral mucositis of WHO grade 4
(Fig. 2) was significantly lower among palifermin
recipients than among placebo recipients (20 per-
cent vs. 62 percent, P<0.001), and the median du-
ration of grade 4 oral mucositis was significantly
shorter among the 21 palifermin recipients than
among the 66 placebo recipients with this adverse
effect (2.0 days [range, 1 to 9] vs. 6.0 days [range,
1 to 37], P=0.004).
Approximately 3 percent of assessments for oral
mucositis were missing. In a sensitivity analysis that
imputed missing oral-mucositis assessments by as-
signing the worst possible score for palifermin and
the best possible score for placebo, the median du-
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Figure 1. Mean Difference between the Placebo Group 
and the Palifermin Group in the Duration of Mucositis 
of WHO Grade 3 or 4, According to Center (Panel A), 
Type of Hematologic Cancer (Panel B), and Number 
of Fractions of Total-Body Irradiation (Panel C).
 
Values in parentheses are the mean differences in dura-
tion between the placebo group and the palifermin group 
(also indicated by the squares) and the numbers of pa-
tients. Horizontal bars represent 95 percent confidence 
intervals. The mean difference could not be calculated 
for center 39, which enrolled only one patient, who re-
ceived palifermin; centers 35, 42, and 46 did not enroll 
any patients. The lower limit of the 95 percent confidence 
interval for the difference in duration exceeded 0 days for 
all centers except center 40 (six patients [four in the pali-
fermin group and two in the placebo group]), for all he-
matologic cancers except leukemia (seven patients [two 
and five, respectively]), and for all three irradiation sub-
groups.
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ration of oral mucositis of grade 3 or 4 was still sig-
nificantly shorter in the palifermin group than in the
placebo group (3.0 days [range, 0 to 20] vs. 8.0 days
[range, 0 to 27], P<0.001).
Similar results were seen for other measure-
ments of oral mucositis among all patients, includ-
ing the median duration of oral mucositis of WHO
grade 2 or higher (8.0 days [range, 0 to 28] in the
palifermin group and 14.3 days [range, 0 to 37] in
the placebo group, P<0.001), the median dura-
tion of oral mucositis of RTOG grade 3 or 4 (0.0
days [range, 0 to 24] and 6.0 days [range, 0 to 54],
P<0.001), and the median duration of lesions of
WCCNR grade 2 or 3 (1.0 day [range, 0 to 36] and
7.0 days [range, 0 to 56], P<0.001).
In agreement with the measurement of oral mu-
cositis, the median scores for the soreness of the
mouth and throat, measured by means of a Likert
(categorical) scale, were significantly lower in the
palifermin group than the placebo group (AUC,
29.0 [range, 0 to 98] vs. 46.8 [range, 0 to 110]; dif-
ference between groups, 38 percent; P<0.001) (Ta-
ble 2). By comparing daily mean scores for soreness
of the mouth and throat with the WHO grade of oral
mucositis, we found that the changes in the patient-
reported scores for soreness of the mouth and
throat preceded the observer-reported changes in
the grade of oral mucositis (Fig. 3). Similar results
were observed for the incidence and duration of
swallowing limitations (Table 2) and other patient-
reported sequelae related to soreness of the mouth
and throat (e.g., ability to drink, eat, talk, and sleep)
(data not shown). Palifermin recipients had signif-
 
Figure 2. Incidence of Oral Mucositis in the Palifermin 
and Placebo Groups.
 
The severity of oral mucositis, as measured by the WHO 
assessment scale, is classified as follows: no oral mu-
cositis (grade 0); soreness or erythema (grade 1); erythe-
ma and ulcers (grade 2); extensive erythema, ulcers, and 
inability to swallow solid food (grade 3); and mucositis 
that prevents any form of alimentation, including swal-
lowing liquids (grade 4). No patient in the placebo group 
had grade 1 oral mucositis. The incidence of oral mu-
cositis of WHO grade 3 or 4 was significantly lower in the 
palifermin group than in the placebo group (P<0.001), 
as was the incidence of grade 4 oral mucositis (P<0.001) 
and the incidence of oral mucositis of grade 2 or higher 
(P<0.01).
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Figure 3. Mean WHO Grade of Oral Mucositis (Panel A) and Scores for Sore-
ness of the Mouth and Throat (Panel B) during the Study.
 
The WHO grades were determined by members of the evaluation team, and 
the scores for soreness of the mouth and throat were determined by the pa-
tients. For days ¡8 (before stem-cell transplantation), 0, 7, 14, 21, and 28, ver-
tical lines represent 95 percent confidence intervals. Mouth soreness was 
graded on a four-point scale, with higher scores indicating greater soreness.
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icantly higher scores for the physical and functional
well-being domains of the Functional Assessment
of Cancer Therapy general questionnaire than did
placebo recipients, also indicating greater improve-
ment (Table 2).
Palifermin recipients used less parenteral or
transdermal opioid analgesics for mucositis than
did placebo recipients, as measured by the median
cumulative dose administered (212 mg of morphine
equivalents [range, 0 to 9418] vs. 535 mg of mor-
phine equivalents [range, 0 to 9418], P<0.001) and
the median duration of administration (7.0 days
[range, 0 to 28] vs. 11.0 days [range, 0 to 32],
P<0.001). Palifermin recipients had a lower inci-
dence of febrile neutropenia than did placebo re-
cipients (75 percent vs. 92 percent, P<0.001). Ex-
ploratory analysis revealed a trend toward a lower
incidence of blood-borne infections in the palifer-
min group than in the placebo group (15 percent vs.
25 percent). The incidence of the use of total par-
enteral nutrition during the study was also lower
among palifermin recipients than among placebo
recipients (31 percent vs. 55 percent, P<0.001).
 
safety
 
The incidence, frequency, and severity of adverse
events were similar in the two groups, and most
were attributable to the underlying cancer, cytotoxic
chemotherapy, or total-body irradiation. Those that
occurred with an incidence that was at least 5 per-
centage points higher in the palifermin group than
in the placebo group are listed in Table 3. Most of
these adverse events were consistent with the phar-
macologic action of palifermin on skin and oral ep-
ithelium (e.g., rash, pruritus, erythema, paresthesia,
mouth and tongue disorders, and taste alteration).
All these events were mild to moderate in severity,
transient (occurring approximately three days after
the third dose of palifermin and lasting approxi-
mately three days), and not a cause for the discon-
tinuation of study drug.
Serious adverse events considered to be related
to treatment occurred in one palifermin recipient
(rash) and one placebo recipient (hypotension). Two
patients died during the study or within 30 days af-
ter the last dose of palifermin or placebo: one pa-
tient in the palifermin group died of veno-occlusive
liver disease, and one patient in the placebo group
died of sepsis. Neither death was considered to be
related to treatment.
Data collection on hematologic recovery after
transplantation was not prospectively specified;
however, by day 12 after transplantation, most pali-
fermin recipients (90 percent) and placebo recipi-
ents (93 percent) had absolute neutrophil counts of
at least 500 per cubic millimeter.
Transient, asymptomatic increases in serum am-
ylase (primarily of salivary origin) and lipase con-
centrations were observed in both groups, with the
peak value for amylase occurring on the last day of
irradiation and the peak value for lipase occurring
after the third dose of study drug. The increases
were higher in the palifermin group (median max-
imal increases from baseline, 166.5 U of amylase
per liter and 17.5 U of lipase per liter) than the pla-
cebo group (92.0 and 12.5 U per liter, respectively).
No additional increase was observed for either en-
zyme, and concentrations returned to near-baseline
values by the day of transplantation.
No clinically significant differences were ob-
served between groups in other laboratory results.
Increases from baseline in WHO toxicity grades of
alanine aminotransferase, aspartate aminotransfer-
ase, bilirubin, alkaline phosphatase, and creatinine
concentrations — primarily one-grade increases —
were observed in less than 35 percent of patients in
each group. Antibodies against palifermin were not
detectable in any patient.
As of November 2003, the median duration of
 
Table 3. Adverse Events Occurring with an Incidence That Was at Least
5 Percentage Points Higher in the Palifermin Group Than in the Placebo Group.
Type of Adverse Event
Palifermin 
Group
(N=106)
Placebo
Group
(N=106)
 
no. of patients (%)
 
Rash 58 (55) 49 (46)
Pruritus 53 (50) 34 (32) 
Erythema 47 (44) 32 (30)
Cough 34 (32) 28 (26)
Edema 29 (27) 18 (17)
Taste alteration 23 (22) 10 (9)
White film coating mouth or tongue 19 (18) 11 (10)
Rhinitis 17 (16) 9 (8)
Arthralgia 14 (13) 7 (7)
Sensation of increased tongue thickness 13 (12) 6 (6)
Perianal pain 12 (11) 5 (5)
Numbness (generally of 1 body area, including 
the feet, fingers, and perioral area)
11 (10) 4 (4)
Taste loss 11 (10) 4 (4)
Paresthesia 10 (9) 1 (1)
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follow-up was 12.6 months in the palifermin group
and 12.0 months in the placebo group. The Kaplan–
Meier estimate of the rate of progression-free sur-
vival at 12 months was 0.69 (95 percent confidence
interval, 0.60 to 0.78) in the palifermin group and
0.73 (95 percent confidence interval, 0.64 to 0.82)
in the placebo group. In follow-up studies to date,
secondary cancers have been diagnosed in three pa-
tients: myelodysplastic syndrome in one patient in
the palifermin group and one patient in the placebo
group and acute lymphoblastic leukemia in one pa-
tient in the palifermin group.
This study provides evidence that palifermin can
significantly reduce, in a clinically meaningful way,
the duration and incidence of oral mucositis after
intensive chemotherapy and radiotherapy and au-
tologous hematopoietic stem-cell transplantation.
Palifermin consistently decreased the incidence and
duration of severe oral mucositis and its clinical se-
quelae independently of the measure used, the par-
ticipating center, the type of underlying disease, and
the number of radiation fractions used. The inten-
sive training of study personnel on the assessment
of oral mucositis enhanced the quality of the data,
and the quantity of missing data was minimal (ap-
proximately 3 percent), increasing confidence in the
results. In addition, observer-reported assessments
concurred with patient-reported assessments of the
soreness of the mouth and throat and related func-
tions, including swallowing.
An important finding was that palifermin mark-
edly reduced the incidence of oral mucositis of
WHO grade 4 (20 percent, as compared with 62 per-
cent in the placebo group; P<0.001), the most de-
bilitating form of oral mucositis, in which oral ali-
mentation is impossible. It is consistent with these
findings that the percentage of patients who re-
ceived total parenteral nutrition, an intervention fre-
quently required for severe oral mucositis,
 
24,25
 
 and
the amount and duration of use of parenteral opioid
analgesics were significantly lower among palifer-
min recipients than placebo recipients.
Our results are particularly compelling because
of the severity and duration of oral mucositis typical-
ly seen in patients with hematologic cancers who
undergo intensive treatment. Although antibiotics
and topical palliative agents can help manage infec-
tions and pain resulting from mild-to-moderate oral
mucositis, none of the growth factors and cyto-
kines unrelated to keratinocyte growth factor test-
ed to date have demonstrated a clear benefit in the
setting of oral mucositis.
 
7,26-30
 
Severe oral mucositis is associated with an in-
creased risk of blood-borne bacterial infections,
which can be life-threatening.
 
31,32
 
 Our exploratory
analysis of blood-borne infections showed a lower
incidence among patients receiving palifermin than
among those receiving placebo. If confirmed by fu-
ture investigations, the ability of palifermin therapy
to reduce the breakdown of mucosal barriers could
decrease the complications caused by systemic in-
fection. In turn, reducing the complications of oral
mucositis could decrease the use of parenteral or
transdermal opioid analgesics for mucositis and
parenteral nutrition and reduce the length of hos-
pitalization.
Palifermin is a growth factor. Keratinocyte
growth-factor receptor is not known to be expressed
in hematologic cancers
 
33
 
; nevertheless, the growth
of second tumors that express this receptor is theo-
retically possible. Evaluation of this risk requires
long-term follow-up, which is ongoing. At 12
months, the progression-free survival rates for pali-
fermin and placebo were nearly identical. In sum-
mary, 60 µg of palifermin per kilogram per day was
associated with reductions in the duration and se-
verity of debilitating oral mucositis and related se-
quelae of high-dose myelosuppressive treatment
with autologous hematopoietic stem-cell support.
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